3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Colonic Neoplasms
2
Carcinoma, Hepatocellular
2
Venous Thrombosis
1
Thrombosis
1
Thromboembolism
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Inflammation
1
Immune System Diseases
1
Gastrointestinal Stromal Tumors
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Duodenal Neoplasms
1
Cholangiocarcinoma
1
Cardiovascular Diseases
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Gemcitabine
95
Cisplatin
72
Capecitabine
39
Oxaliplatin
38
durvalumab
29
Fluorouracil
27
pembrolizumab
26
Leucovorin
23
S 1 (combination)
19
Nivolumab
14
Irinotecan
14
lenvatinib
13
Bevacizumab
13
tremelimumab
10
130-nm albumin-bound paclitaxel
9
apatinib
8
Trastuzumab
7
Injections
7
Immune Checkpoint Inhibitors
7
Docetaxel
7
Albumin-Bound Paclitaxel
7
Paclitaxel
6
Drug Therapy
6
titanium silicide
5
surufatinib
5
irinotecan sucrosofate
5
gemcitabine-oxaliplatin regimen
5
envafolimab
5
camrelizumab
5
atezolizumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Biliary Tract Neoplasms
×
Rivaroxaban
×
Gastrointestinal
×
Clear all
NCT03139487
2020-01-06
PRIORITY
Asan Medical Center
Phase 2
Unknown
176 enrolled